Sagimet Advances MASH Combination Therapy With Phase 1 PK Data
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
liver fibrosis
Advertisement
Health Canada Grants Conditional Approval for Wegovy® in MASH
MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...
Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum
Dateline — San Diego, California, November 7, 2025:Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a...
Sagimet Begins Phase 1 Trial of Denifanstat-Resmetirom Combo in MASH
SAN MATEO, Calif., Oct. 1, 2025 — Sagimet Biosciences announced that it has dosed the first participants in a...
Advertisement
